CTLA4 and neoplasm: The rationale to combine anti-PD-1 and anti-CTLA-4 antibodies relays in theirdifferent mechanisms of action and their ability to modulate different phases of theinteraction of tumor and immune system: anti-CTLA-4 acts mainly in the priming phasewhile anti-PD-1 blocks the effector phase in local tumor tissue.